Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Understanding the Role of Pro-resolving Lipid Mediators in Infectious Keratitis.

Berger EA.

Adv Exp Med Biol. 2019;1161:3-12. doi: 10.1007/978-3-030-21735-8_2.

PMID:
31562617
2.

Application of a Flow-Based Hollow-Fiber Co-Culture System to Study Cellular Influences under Hyperglycemic Conditions.

Ebrahim AS, Carion TW, Strand E, Young LA, Shi H, Berger EA.

Sci Rep. 2019 Mar 7;9(1):3771. doi: 10.1038/s41598-019-40555-0.

3.

Glycoprotein K8.1A of Kaposi's Sarcoma-Associated Herpesvirus Is a Critical B Cell Tropism Determinant Independent of Its Heparan Sulfate Binding Activity.

Dollery SJ, Santiago-Crespo RJ, Chatterjee D, Berger EA.

J Virol. 2019 Mar 5;93(6). pii: e01876-18. doi: 10.1128/JVI.01876-18. Print 2019 Mar 15.

4.

VIP modulates the ALX/FPR2 receptor axis toward inflammation resolution in a mouse model of bacterial keratitis.

Carion TW, Kracht D, Strand E, David E, McWhirter C, Ebrahim AS, Berger EA.

Prostaglandins Other Lipid Mediat. 2019 Feb;140:18-25. doi: 10.1016/j.prostaglandins.2018.12.001. Epub 2018 Dec 4. Review.

PMID:
30529189
5.

Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas aeruginosa-Induced Keratitis.

Carion TW, Ebrahim AS, Kracht D, Agrawal A, Strand E, Kaddurah O, McWhirter CR, Sosne G, Berger EA.

Cells. 2018 Sep 20;7(10). pii: E145. doi: 10.3390/cells7100145.

6.

A Contrast in Pathogenic Responses between C57BL/6J and BALB/cJ Mice Using a Model of Retinal Injury.

Shi H, Ebrahim AS, Berger EA.

Am J Pathol. 2018 Dec;188(12):2717-2728. doi: 10.1016/j.ajpath.2018.08.010. Epub 2018 Sep 18.

PMID:
30236476
7.

Immunoregulatory role of 15-lipoxygenase in the pathogenesis of bacterial keratitis.

Carion TW, Greenwood M, Ebrahim AS, Jerome A, Suvas S, Gronert K, Berger EA.

FASEB J. 2018 Sep;32(9):5026-5038. doi: 10.1096/fj.201701502R. Epub 2018 Apr 13.

8.

Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer.

Zhang P, Gorman J, Geng H, Liu Q, Lin Y, Tsybovsky Y, Go EP, Dey B, Andine T, Kwon A, Patel M, Gururani D, Uddin F, Guzzo C, Cimbro R, Miao H, McKee K, Chuang GY, Martin L, Sironi F, Malnati MS, Desaire H, Berger EA, Mascola JR, Dolan MA, Kwong PD, Lusso P.

Cell Host Microbe. 2018 Jun 13;23(6):832-844.e6. doi: 10.1016/j.chom.2018.05.002.

9.

Characterization of Site-Specific Phosphorylation of NF-κB p65 in Retinal Cells in Response to High Glucose and Cytokine Polarization.

Shi H, Berger EA.

Mediators Inflamm. 2018 Apr 26;2018:3020675. doi: 10.1155/2018/3020675. eCollection 2018.

10.

Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication.

Haran KP, Hajduczki A, Pampusch MS, Mwakalundwa G, Vargas-Inchaustegui DA, Rakasz EG, Connick E, Berger EA, Skinner PJ.

Front Immunol. 2018 Mar 20;9:492. doi: 10.3389/fimmu.2018.00492. eCollection 2018.

11.

Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity.

Ghanem MH, Bolivar-Wagers S, Dey B, Hajduczki A, Vargas-Inchaustegui DA, Danielson DT, Bundoc V, Liu L, Berger EA.

Cytotherapy. 2018 Mar;20(3):407-419. doi: 10.1016/j.jcyt.2017.11.001. Epub 2018 Jan 3.

PMID:
29306566
12.

A regulatory role for β-adrenergic receptors regarding the resolvin D1 (RvD1) pathway in the diabetic retina.

Shi H, Carion TW, Jiang Y, Chahine A, Steinle JJ, Berger EA.

PLoS One. 2017 Nov 2;12(11):e0185383. doi: 10.1371/journal.pone.0185383. eCollection 2017.

13.

Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort.

Fink E, Fuller K, Agan B, Berger EA, Saphire A, Quinnan GV, Elder JH.

AIDS Res Hum Retroviruses. 2016 Dec;32(12):1187-1197. Epub 2016 Nov 21.

14.

Assembly and release of infectious hepatitis C virus involving unusual organization of the secretory pathway.

Triyatni M, Berger EA, Saunier B.

World J Hepatol. 2016 Jul 8;8(19):796-814. doi: 10.4254/wjh.v8.i19.796.

15.

VIP protects human retinal microvascular endothelial cells against high glucose-induced increases in TNF-α and enhances RvD1.

Shi H, Carion TW, Jiang Y, Steinle JJ, Berger EA.

Prostaglandins Other Lipid Mediat. 2016 Mar;123:28-32. doi: 10.1016/j.prostaglandins.2016.03.001. Epub 2016 Mar 26.

16.

β-Adrenergic receptor agonist, compound 49b, inhibits TLR4 signaling pathway in diabetic retina.

Berger EA, Carion TW, Jiang Y, Liu L, Chahine A, Walker RJ, Steinle JJ.

Immunol Cell Biol. 2016 Aug;94(7):656-61. doi: 10.1038/icb.2016.21. Epub 2016 Feb 18.

17.

Efficacy of VIP as Treatment for Bacteria-Induced Keratitis Against Multiple Pseudomonas aeruginosa Strains.

Carion TW, McWhirter CR, Grewal DK, Berger EA.

Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6932-40. doi: 10.1167/iovs.15-17315.

18.

Finding Fusin/CXCR4, the First "2nd Receptor" for HIV Entry.

Berger EA.

Front Immunol. 2015 Jun 8;6:283. doi: 10.3389/fimmu.2015.00283. eCollection 2015. Review. No abstract available.

19.

Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, Rosenberg SA, Dey B, Berger EA.

J Virol. 2015 Jul;89(13):6685-94. doi: 10.1128/JVI.00474-15. Epub 2015 Apr 15.

20.

Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection.

Dey B, Berger EA.

Curr Opin HIV AIDS. 2015 May;10(3):207-13. doi: 10.1097/COH.0000000000000151. Review.

21.

A comparison of quality outcome measures in patients having a hysterectomy for benign disease: robotic vs. non-robotic approaches.

Martino MA, Berger EA, McFetridge JT, Shubella J, Gosciniak G, Wejkszner T, Kainz GF, Patriarco J, Thomas MB, Boulay R.

J Minim Invasive Gynecol. 2014 May-Jun;21(3):389-93. doi: 10.1016/j.jmig.2013.10.008. Epub 2013 Oct 26.

PMID:
24513969
22.

Targeted cytotoxic therapy kills persisting HIV infected cells during ART.

Denton PW, Long JM, Wietgrefe SW, Sykes C, Spagnuolo RA, Snyder OD, Perkey K, Archin NM, Choudhary SK, Yang K, Hudgens MG, Pastan I, Haase AT, Kashuba AD, Berger EA, Margolis DM, Garcia JV.

PLoS Pathog. 2014 Jan;10(1):e1003872. doi: 10.1371/journal.ppat.1003872. Epub 2014 Jan 9.

23.

Efficient infection of a human B cell line with cell-free Kaposi's sarcoma-associated herpesvirus.

Dollery SJ, Santiago-Crespo RJ, Kardava L, Moir S, Berger EA.

J Virol. 2014 Feb;88(3):1748-57. doi: 10.1128/JVI.03063-13. Epub 2013 Nov 20.

24.

Gradient evolution of body colouration in surface- and cave-dwelling Poecilia mexicana and the role of phenotype-assortative female mate choice.

Bierbach D, Penshorn M, Hamfler S, Herbert DB, Appel J, Meyer P, Slattery P, Charaf S, Wolf R, Völker J, Berger EA, Dröge J, Wolf K, Riesch R, Arias-Rodriguez L, Indy JR, Plath M.

Biomed Res Int. 2013;2013:148348. doi: 10.1155/2013/148348. Epub 2013 Sep 24.

25.

HIF-1α is essential for effective PMN bacterial killing, antimicrobial peptide production and apoptosis in Pseudomonas aeruginosa keratitis.

Berger EA, McClellan SA, Vistisen KS, Hazlett LD.

PLoS Pathog. 2013;9(7):e1003457. doi: 10.1371/journal.ppat.1003457. Epub 2013 Jul 18.

26.

Blocking HIV-1 gp120 at the Phe43 cavity: if the extension fits….

Dey B, Berger EA.

Structure. 2013 Jun 4;21(6):871-2. doi: 10.1016/j.str.2013.05.004.

27.

Mammalian target of rapamycin regulates IL-10 and resistance to Pseudomonas aeruginosa corneal infection.

Foldenauer ME, McClellan SA, Berger EA, Hazlett LD.

J Immunol. 2013 Jun 1;190(11):5649-58. doi: 10.4049/jimmunol.1203094. Epub 2013 Apr 26.

28.

Effects of VIP on corneal reconstitution and homeostasis following Pseudomonas aeruginosa induced keratitis.

Berger EA, Vistisen KS, Barrett RP, Hazlett LD.

Invest Ophthalmol Vis Sci. 2012 Nov 1;53(12):7432-9. doi: 10.1167/iovs.12-9894.

29.
30.

Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer.

Liu L, Cimbro R, Lusso P, Berger EA.

Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20148-53. doi: 10.1073/pnas.1104840108. Epub 2011 Nov 29.

31.

VIP and growth factors in the infected cornea.

Jiang X, McClellan SA, Barrett RP, Berger EA, Zhang Y, Hazlett LD.

Invest Ophthalmol Vis Sci. 2011 Aug 3;52(9):6154-61. doi: 10.1167/iovs.10-6943.

32.

Testican-1 promotes resistance against Pseudomonas aeruginosa-induced keratitis through regulation of MMP-2 expression and activation.

Berger EA, McClellan SA, Barrett RP, Hazlett LD.

Invest Ophthalmol Vis Sci. 2011 Jul 18;52(8):5339-46. doi: 10.1167/iovs.10-6920.

33.

Pillars article: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996. 272: 872-877.

Feng Y, Broder CC, Kennedy PE, Berger EA.

J Immunol. 2011 Jun 1;186(11):6076-81. No abstract available.

34.

A new model to produce infectious hepatitis C virus without the replication requirement.

Triyatni M, Berger EA, Saunier B.

PLoS Pathog. 2011 Apr;7(4):e1001333. doi: 10.1371/journal.ppat.1001333. Epub 2011 Apr 14. Review.

35.

An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection.

Cai Y, Berger EA.

Antiviral Res. 2011 Jun;90(3):143-50. doi: 10.1016/j.antiviral.2011.03.175. Epub 2011 Mar 31.

36.
37.

VIP promotes resistance in the Pseudomonas aeruginosa-infected cornea by modulating adhesion molecule expression.

Berger EA, McClellan SA, Barrett RP, Hazlett LD.

Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5776-82. doi: 10.1167/iovs.09-4917. Epub 2010 Jun 30.

38.

Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

Berger EA, Pastan I.

PLoS Pathog. 2010 Jun 10;6(6):e1000803. doi: 10.1371/journal.ppat.1000803. No abstract available.

39.

sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.

Lagenaur LA, Villarroel VA, Bundoc V, Dey B, Berger EA.

Retrovirology. 2010 Feb 16;7:11. doi: 10.1186/1742-4690-7-11.

40.
41.

Vaccinia-based reporter gene cell-fusion assays to quantitate functional interactions of HIV envelope glycoprotein with receptors.

Dey B, Berger EA.

Curr Protoc Immunol. 2003 May;Chapter 12:Unit 12.10. doi: 10.1002/0471142735.im1210s54. Review.

PMID:
18432897
42.

HIV gp120 interactions with coreceptors: insights from studies with CCR5-based peptides.

Berger EA, Alkhatib G.

Eur J Med Res. 2007 Oct 15;12(9):403-7. Review.

PMID:
17933721
43.

HIV coreceptors: from discovery and designation to new paradigms and promise.

Alkhatib G, Berger EA.

Eur J Med Res. 2007 Oct 15;12(9):375-84. Review.

PMID:
17933717
44.

Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques.

Kennedy PE, Bera TK, Wang QC, Gallo M, Wagner W, Lewis MG, Berger EA, Pastan I.

J Leukoc Biol. 2006 Nov;80(5):1175-82. Epub 2006 Aug 21.

PMID:
16923920
45.
46.
47.

An anti-HIV microbicide comes alive.

Lagenaur LA, Berger EA.

Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12294-5. Epub 2005 Aug 23. No abstract available.

48.

CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion.

Cassiani-Ingoni R, Greenstone HL, Donati D, Fogdell-Hahn A, Martinelli E, Refai D, Martin R, Berger EA, Jacobson S.

Glia. 2005 Nov 15;52(3):252-8.

PMID:
15920733
49.
50.

Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5.

Agrawal L, VanHorn-Ali Z, Berger EA, Alkhatib G.

Blood. 2004 Feb 15;103(4):1211-7. Epub 2003 Oct 23.

PMID:
14576050

Supplemental Content

Loading ...
Support Center